SCHEMBL19209370

SCHEMBL19209370

C/C(Br)=C(/C=C/C(=O)c1cccc(Cl)c1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
MAPT P10636 2/20 0.55
GAA P10253 1/20 0.55
HPGD P15428 1/20 0.55
HTT P42858 1/20 0.55
MAOB P27338 5/20 0.51
MAOA P21397 3/20 0.51
PTPN1 P18031 1/20 0.47
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
CYP1A1 P04798 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP1B1 Q16678 1/20 0.45
AKR1C3 P42330 2/20 0.44
AKR1C2 P52895 2/20 0.44
AKR1C1 Q04828 2/20 0.44
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19243110 1.00 ALDH1A1 (0.55) ALDH1A1MAPTGAAHPGDHTT
SCHEMBL19209371 1.00 ALDH1A1 (0.55) ALDH1A1MAPTGAAHPGDHTT
SCHEMBL20677750 0.85 MAOB (0.54) ALDH1A1MAPTGAAHPGDHTT
SCHEMBL20684800 0.85 MAOB (0.54) ALDH1A1MAPTGAAHPGDHTT
SCHEMBL20677751 0.85 MAOB (0.54) ALDH1A1MAPTGAAHPGDHTT
SCHEMBL20677730 0.85 RAB9A (0.51) ALDH1A1MAPTGAAHPGDHTT
SCHEMBL19243107 0.85 RECQL (0.50) ALDH1A1MAPTHPGDHTTMAOB
SCHEMBL19209337 0.85 RECQL (0.50) ALDH1A1MAPTHPGDHTTMAOB
SCHEMBL19209338 0.85 RECQL (0.50) ALDH1A1MAPTHPGDHTTMAOB
SCHEMBL31167601 0.81 ALDH1A1 (0.71) ALDH1A1MAPTGAAHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2019-01-31 US disclosed
EP-3400226-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER Emcure Pharmaceuticals Limited (IN) 2018-11-14 EP disclosed
WO-2017134555-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER IDO1, IDO2, TDO2 ALDH1A1 946/4885MAPT 3786/4885GAA 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.